EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial

Carsten Flohr iD, Anna Rosala-Hallas, Ashley P Jones, Paula Beattie, Susannah Baron, Fiona Browne, Sara J Brown, Joanna E Gach, Danielle Greenblatt, Ross Hearn, Eva Hilger, Ben Esdaile und 18 weitere

British Journal of Dermatology · 16.11.2023 · 189 (6) · 674-684

DOI: 10.1093/bjd/ljad281 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, online erschienen am 19.09.2023. Verfasst von Carsten Flohr und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Dermatology, St John's Institute of Dermatology, King's College London and Guy's and St Thomas' NHS Foundation Trust, London…. Hauptthemen laut MEDLINE: Cyclosporine, Dermatitis, Atopic. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Medical Research Council/National Institute for Health Research Efficacy and Mechanism Evaluation Board, UK Medical Research Council, National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Conventional systemic drugs are used to treat children and young people (CYP) with severe atopic dermatitis (AD) worldwide, but no robust randomized controlled trial (RCT) evidence exists regarding their efficacy and safety in this population. While novel therapies have expanded therapeutic options, their high cost means traditional agents remain important, especially in lower-resource settings.

Objectives

To compare the safety and efficacy of ciclosporin (CyA) with methotrexate (MTX) in CYP with severe AD in the TREatment of severe Atopic Eczema Trial (TREAT) trial.

Methods

We conducted a parallel group assessor-blinded RCT in 13 UK and Irish centres. Eligible participants aged 2–16 years and unresponsive to potent topical treatment were randomized to either oral CyA (4 mg kg–1 daily) or MTX (0.4 mg kg–1 weekly) for 36 weeks and followed-up for 24 weeks. Co-primary outcomes were change from baseline to 12 weeks in Objective Severity Scoring of Atopic Dermatitis (o-SCORAD) and time to first significant flare (relapse) after treatment cessation. Secondary outcomes included change in quality of life (QoL) from baseline to 60 weeks; number of participant-reported flares following treatment cessation; proportion of participants achieving ≥ 50% improvement in Eczema Area and Severity Index (EASI 50) and ≥ 75% improvement in EASI (EASI 75); and stratification of outcomes by filaggrin status.

Results

In total, 103 participants were randomized (May 2016–February 2019): 52 to CyA and 51 to MTX. CyA showed greater improvement in disease severity by 12 weeks [mean difference in o-SCORAD –5.69, 97.5% confidence interval (CI) –10.81 to –0.57 (P = 0.01)]. More participants achieved ≥ 50% improvement in o-SCORAD (o-SCORAD 50) at 12 weeks in the CyA arm vs. the MTX arm [odds ratio (OR) 2.60, 95% CI 1.23–5.49; P = 0.01]. By 60 weeks MTX was superior (OR 0.33, 95% CI 0.13–0.85; P = 0.02), a trend also seen for ≥ 75% improvement in o-SCORAD (o-SCORAD 75), EASI 50 and EASI 75. Participant-reported flares post-treatment were higher in the CyA arm (OR 3.22, 95% CI 0.42–6.01; P = 0.02). QoL improved with both treatments and was sustained after treatment cessation. Filaggrin status did not affect outcomes. The frequency of adverse events (AEs) was comparable between both treatments. Five (10%) participants on CyA and seven (14%) on MTX experienced a serious AE.

Conclusions

Both CyA and MTX proved effective in CYP with severe AD over 36 weeks. Participants who received CyA showed a more rapid response to treatment, while MTX induced more sustained disease control after discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclosporineDermatitis, AtopicChildHumansAdolescentMethotrexateFilaggrin ProteinsOdds RatioTreatment OutcomeSeverity of Illness IndexDouble-Blind Method

Substanzen

CyclosporineMethotrexateFilaggrin Proteins

Autor:innen und Institutionen

  • Department of Paediatric Dermatology, St John's Institute of Dermatology, King's College London and Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK.
  • Royal Hospital for Children NHS Trust, Glasgow, UK.
  • Paediatric Dermatology, Children's Health Ireland at Crumlin, Dublin, Ireland.
  • Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, UK.
  • University Hospitals Coventry and Warwickshire, Coventry, UK.

ORCID-Profile: Carsten Flohr, Jane Ravenscroft, Leonie S Taams, Bjorn R Thomas, Tracey H Sach

Förderung

  • UK Medical Research Council/National Institute for Health Research Efficacy and Mechanism Evaluation Board
  • UK Medical Research Council
  • National Institute for Health and Care Research
  • NIH

Zitieren

APA

Flohr, C., Rosala-Hallas, A., Jones, A. P., Beattie, P., Baron, S., Browne, F., Brown, S. J., Gach, J. E., Greenblatt, D., Hearn, R., Hilger, E., Esdaile, B., Cork, M. J., Howard, E., Lovgren, M. L., August, S., Ashoor, F., Williamson, P. R., McPherson, T., …, & TREAT Trial Investigators (2023). Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial. British Journal of Dermatology, 189(6), 674-684. https://doi.org/10.1093/bjd/ljad281

Vancouver

Flohr C, Rosala-Hallas A, Jones AP, Beattie P, Baron S, Browne F, et al. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial. British Journal of Dermatology. 2023;189(6):674-684. doi:10.1093/bjd/ljad281

BibTeX
@article{Flohr2023,
  author = {Flohr, Carsten and Rosala-Hallas, Anna and Jones, Ashley P and Beattie, Paula and Baron, Susannah and Browne, Fiona and Brown, Sara J and Gach, Joanna E and Greenblatt, Danielle and Hearn, Ross and Hilger, Eva and Esdaile, Ben and Cork, Michael J and Howard, Emma and Lovgren, Marie-Louise and August, Suzannah and Ashoor, Farhiya and Williamson, Paula R and McPherson, Tess and O'Kane, Donal and Ravenscroft, Jane and Shaw, Lindsay and Sinha, Manish D and Spowart, Catherine and Taams, Leonie S and Thomas, Bjorn R and Wan, Mandy and Sach, Tracey H and Irvine, Alan D and TREAT Trial Investigators, TREAT Trial Investigators},
  title = {Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial},
  journal = {British Journal of Dermatology},
  year = {2023},
  volume = {189},
  number = {6},
  pages = {674--684},
  doi = {10.1093/bjd/ljad281}
}
Kostenlos starten →